ContactCredit ReportFinancialsPeopleOwnershipLatest ActivityMutual CompaniesDocumentsRepayment History

Cytocell Limited

Cytocell Limited is an active company incorporated on 8 June 2001 with the registered office located in Cambridge, Cambridgeshire. Cytocell Limited was registered 24 years ago.
Status
Active
Active since 20 years ago
Company No
04231155
Private limited company
Age
24 years
Incorporated 8 June 2001
Size
Unreported
Confirmation
Submitted
Dated 4 June 2025 (5 months ago)
Next confirmation dated 4 June 2026
Due by 18 June 2026 (7 months remaining)
Last change occurred 8 years ago
Accounts
Submitted
For period 1 Apr31 Mar 2024 (1 year)
Accounts type is Full
Next accounts for period 31 March 2025
Due by 31 December 2025 (1 month remaining)
Address
Oxford Gene Technology 418 Cambridge Science Park
Milton Road
Cambridge
CB4 0PZ
United Kingdom
Same address for the past 4 years
Telephone
01223294048
Email
Available in Endole App
People
Officers
9
Shareholders
1
Controllers (PSC)
1
Director • Japanese • Lives in Japan • Born in Jun 1975
Director • British • Lives in UK • Born in Feb 1958
Director • Ceo • British • Lives in England • Born in Aug 1971
Director • Japanese • Lives in Japan • Born in Apr 1969
Director • Cfo • British • Lives in England • Born in Oct 1980
Shareholders, PSCs & Group Structure
See who truly controls a company with full PSC, Shareholder, and Group Structure exploration
Mutual Companies
Oxford Gene Technology Limited
Dr Michael Robert Evans, Mr Gregory Alun Williams, and 2 more are mutual people.
Active
Oxford Gene Technology (Operations) Ltd
Dr Michael Robert Evans, Mr Gregory Alun Williams, and 2 more are mutual people.
Active
Oxford Gene Technology Ip Limited
Dr Michael Robert Evans, Mr Gregory Alun Williams, and 2 more are mutual people.
Active
Oxford Gene Technology (Southern) Limited
Dr Michael Robert Evans, Mr Gregory Alun Williams, and 1 more are mutual people.
Active
Tozaro Limited
Dr Michael Robert Evans is a mutual person.
Active
Financials
Net Assets, Total Assets & Total Liabilities (2014–2024)
Period Ended
31 Mar 2024
For period 31 Mar31 Mar 2024
Traded for 12 months
Cash in Bank
£896K
Decreased by £614K (-41%)
Turnover
£13.31M
Decreased by £80K (-1%)
Employees
77
Increased by 5 (+7%)
Total Assets
£63.26M
Increased by £5.83M (+10%)
Total Liabilities
-£28.32M
Increased by £3.05M (+12%)
Net Assets
£34.94M
Increased by £2.78M (+9%)
Debt Ratio (%)
45%
Increased by 0.77% (+2%)
Latest Activity
Michael Robert Evans Resigned
1 Month Ago on 25 Sep 2025
Confirmation Submitted
5 Months Ago on 4 Jun 2025
Mr Kenji Iwakabe Appointed
5 Months Ago on 7 May 2025
Mr Naohiko Matsuo Appointed
7 Months Ago on 27 Mar 2025
Takashi Ono Resigned
7 Months Ago on 27 Mar 2025
Kondo Naoto Resigned
7 Months Ago on 27 Mar 2025
Full Accounts Submitted
10 Months Ago on 20 Dec 2024
Confirmation Submitted
1 Year 4 Months Ago on 17 Jun 2024
Mr Takashi Ono Appointed
1 Year 5 Months Ago on 16 May 2024
Mamoru Kubota Resigned
1 Year 7 Months Ago on 28 Mar 2024
Get Credit Report
Discover Cytocell Limited's Credit Score, how much credit you can offer them, and how likely they are to repay you
Documents
Termination of appointment of Michael Robert Evans as a director on 25 September 2025
Submitted on 29 Sep 2025
Confirmation statement made on 4 June 2025 with no updates
Submitted on 4 Jun 2025
Appointment of Mr Kenji Iwakabe as a director on 7 May 2025
Submitted on 8 May 2025
Appointment of Mr Naohiko Matsuo as a director on 27 March 2025
Submitted on 9 Apr 2025
Termination of appointment of Takashi Ono as a director on 27 March 2025
Submitted on 8 Apr 2025
Termination of appointment of Kondo Naoto as a director on 27 March 2025
Submitted on 8 Apr 2025
Full accounts made up to 31 March 2024
Submitted on 20 Dec 2024
Confirmation statement made on 8 June 2024 with no updates
Submitted on 17 Jun 2024
Appointment of Mr Takashi Ono as a director on 16 May 2024
Submitted on 17 May 2024
Termination of appointment of Mamoru Kubota as a director on 28 March 2024
Submitted on 4 Apr 2024
Repayment History
Understand how businesses repay their debts and see how they're performing year‐on‐year